Trial Profile
A single-dose, open-label, three-way crossover study, to assess the effect of pre-dose meal composition on the pharmacokinetics of gastro-retentive AP-DLD 50/500mg
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Nov 2019
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology
- 14 Oct 2015 New trial record
- 12 Oct 2015 Results published in an Intec Pharma media release.